{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:40:34Z","timestamp":1773290434102,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Historically, oesophageal and gastro-oesophageal junction adenocarcinomas were associated with a poor prognosis. The advent of neoadjuvant therapy has transformed the management of oesophageal and gastro-oesophageal junction adenocarcinomas further and offers the possibility to reverse disease progression, eliminate micrometastasis, and offer potentially better outcomes for these patients. This review provides an overview of landmark clinical trials in this area, with different treatment regimens considered over the years as well as potential therapeutic agents on the horizon that may transform the management of oesophageal and gastro-oesophageal junction adenocarcinomas further.<\/jats:p>","DOI":"10.3390\/cancers15194741","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:49:14Z","timestamp":1695786554000},"page":"4741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-1803","authenticated-orcid":false,"given":"Alexander A.","family":"Dermanis","sequence":"first","affiliation":[{"name":"Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2GW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivesh K.","family":"Kamarajah","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2GW, UK"},{"name":"Academic Department of Surgery, Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2GW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref_1","unstructured":"Mukkamalla, S.K.R., Recio-Boiles, A., and Babiker, H.M. (2023, April 25). Esophageal Cancer, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459267\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.21037\/jtd.2018.11.143","article-title":"The optimal neoadjuvant treatment of locally advanced esophageal cancer","volume":"11","author":"Eyck","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/1759-7714.14069","article-title":"History and current situation of neoadjuvant treatment for locally advanced esophageal cancer","volume":"12","author":"Li","year":"2021","journal-title":"Thorac. Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1097-0142(1967)20:5<778::AID-CNCR2820200532>3.0.CO;2-B","article-title":"Surgical treatment combined with preoperative concentrated irradiation for esophageal cancer","volume":"20","author":"Nakayama","year":"1967","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0360-3016(92)90708-P","article-title":"Patterns of failure following combined modality therapy for esophageal cancer, 1984\u20131990","volume":"24","author":"Kavanagh","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000226622","article-title":"Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer","volume":"45","author":"Nagy","year":"1988","journal-title":"Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM199812313392704","article-title":"Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer","volume":"339","author":"Kelsen","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2006.10.4760","article-title":"Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer","volume":"25","author":"Kelsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Medical Research Council Oesophageal Cancer Working Group (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet, 359, 1727\u20131733.","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_14","first-page":"829","article-title":"Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus","volume":"36","author":"Ojima","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/cas.12274","article-title":"Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma","volume":"104","author":"Hara","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdr465","article-title":"Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A multicenter phase II trial","volume":"23","author":"Ferri","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/cam4.885","article-title":"Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma","volume":"5","author":"Fiteni","year":"2016","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis","volume":"8","author":"Gebski","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ijc.31312","article-title":"Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis","volume":"143","author":"Chan","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12957-020-01830-x","article-title":"Neoadjuvant strategies in resectable carcinoma esophagus: A meta-analysis of randomized trials","volume":"18","author":"Kumar","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sato, Y., Motoyama, S., Wada, Y., Wakita, A., Kawakita, Y., Nagaki, Y., Terata, K., Imai, K., Anbai, A., and Hashimoto, M. (2021). Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers, 13.","DOI":"10.3390\/cancers13050983"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJM199608153350702","article-title":"A comparison of multimodal therapy and surgery for esophageal adenocarcinoma","volume":"335","author":"Walsh","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial","volume":"36","author":"Yang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: Final analysis of randomized controlled phase III trial FFCD 9901","volume":"32","author":"Mariette","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.03.025","article-title":"Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: A multicentre randomised phase II trial (NCCTG N0849 [Alliance])","volume":"150","author":"Yoon","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/annonc\/mdt339","article-title":"A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer","volume":"24","author":"Ajani","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III Comparison of Preoperative Chemotherapy Compared with Chemoradiotherapy in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_36","first-page":"doy078","article-title":"Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: Long-term results of a randomized clinical trial","volume":"32","author":"Klevebro","year":"2019","journal-title":"Dis. Esophagus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"628706","DOI":"10.3389\/fonc.2021.628706","article-title":"The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients","volume":"11","author":"Yuan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Reynolds, J.V., Preston, S.R., O\u2019Neill, B., Baeksgaard, L., Griffin, S.M., Mariette, C., Cuffe, S., Cunningham, M., Crosby, T., and Parker, I. (2017). ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3386-2"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hoeppner, J., Lordick, F., Brunner, T., Glatz, T., Bronsert, P., R\u00f6thling, N., Schmoor, C., Lorenz, D., Ell, C., and Hopt, U.T. (2016). ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2564-y"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13063-021-05274-w","article-title":"Updated protocol of the SANO trial: A stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer","volume":"22","author":"Eyck","year":"2021","journal-title":"Trials"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hipp, J., Nagavci, B., Schmoor, C., Meerpohl, J., Hoeppner, J., and Schmucker, C. (2021). Post-Neoadjuvant Surveillance and Surgery as Needed Compared with Post-Neoadjuvant Surgery on Principle in Multimodal Treatment for Esophageal Cancer: A Scoping Review. Cancers, 13.","DOI":"10.3390\/cancers13030429"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"734581","DOI":"10.3389\/fonc.2022.734581","article-title":"Neoadjuvant Therapy for Locally Advanced Esophageal Cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung","year":"2021","journal-title":"Future Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.19.01814","article-title":"Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab with Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study","volume":"38","author":"Stroes","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2010.31.9715","article-title":"Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB\/II Trial (SAKK 75\/06)","volume":"29","author":"Ruhstaller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdy105","article-title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: A randomized, open-label, phase III trial (SAKK 75\/08)","volume":"29","author":"Ruhstaller","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2021.39.15_suppl.4050","article-title":"Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric\/gastroesophageal junction (GEJ) adenocarcinoma","volume":"39","author":"Li","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16098","DOI":"10.1002\/cam4.6263","article-title":"A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2019.37.4_suppl.142","article-title":"Neoadjuvant Nivolumab Plus Concurrent Chemoradiation in Stage II\/III Esophageal\/Gastroesophageal Junction Cancer","volume":"37","author":"Kelly","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","article-title":"Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)","volume":"27","author":"Gisbertz","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:59:13Z","timestamp":1760129953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":54,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194741"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194741","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}